BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2022 8:36:01 AM | Browse: 552 | Download: 1705
 |
Received |
|
2021-11-27 07:20 |
|
Peer-Review Started |
|
2021-11-27 07:23 |
|
First Decision by Editorial Office Director |
|
2022-01-12 01:06 |
|
Return for Revision |
|
2022-01-12 01:06 |
|
Revised |
|
2022-01-22 16:39 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-30 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-06-03 21:20 |
|
Articles in Press |
|
2022-06-03 21:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-06-30 13:06 |
|
Publish the Manuscript Online |
|
2022-07-11 08:36 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ miscrosatellite-stable type endometrial cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chong-Ya Zhai, Lu-Xi Yin and Wei-Dong Han |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Hangzhou Health and Family Planning and Science and Technology Program |
OO20190347 |
|
| Corresponding Author |
Wei-Dong Han, MD, Chief Doctor, Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, No. 3 Qingchun East Road, Hangzhou 310020, Zhejiang Province, China. hanwd@zju.edu.cn |
| Key Words |
Refractory endometrial cancer; Proficient mismatch repair; Miscrosatellite-stable; Immunotherapy; Case report |
| Core Tip |
Endometrial cancer (EC) with proficient mismatch repair/miscrosatellite-stable (pMMR/MSS)-type hardly responds to immune checkpoint therapy. This case reported a satisfactory outcome with well-tolerated toxicities using toripalimab combined with anlotinib treatment in an EC patient with pMMR/MSS-type. Although need further clinical evidence, programmed cell death-1 inhibitor combined anti-angiogenesis therapy may present an option for EC patients with pMMR/MSS-type after multi-line treatment. |
| Publish Date |
2022-07-11 08:36 |
| Citation |
Zhai CY, Yin LX, Han WD. Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ miscrosatellite-stable type endometrial cancer: A case report. World J Clin Cases 2022; 10(21): 7474-7482 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i21/7474.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i21.7474 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
